The Profiles of Tet-Mediated DNA Hydroxymethylation in Human Gliomas

Aneta Brągiel-Pieczonka, Gabriela Lipka, Angelika Stapińska-Syniec, Michał Czyżewski, Katarzyna Żybura-Broda, Michał Sobstyl, Marcin Ryński and Marta Grabiec

1 Department of Clinical Cytology, Centre of Postgraduate Medical Education, Warsaw, Poland, 2 Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, 3 Department of Radiology, Institute of Psychiatry and Neurology, Warsaw, Poland

Gliomas are the most common primary malignant intracranial brain tumors. Their proliferative and invasive behavior is controlled by various epigenetic mechanisms. 5-hydroxymethylcytosine (5-hmC) is one of the epigenetic DNA modifications that employs ten-eleven translocation (TET) enzymes to its oxidation. Previous studies demonstrated altered expression of 5-hmC across gliomagenesis. However, its contribution to the initiation and progression of human gliomas still remains unknown. To characterize the expression profiles of 5-hmC and TET in human glioma samples we used the EpiJET 5-hmC and 5-mC Analysis Kit, quantitative real-time PCR, and Western blot analysis. A continuous decline of 5-hmC levels was observed in solid tissue across glioma grades. However, in glioblastoma (GBM), we documented uncommon heterogeneity in 5-hmC expression. Further analysis showed that the levels of TET proteins, but not their transcripts, may influence the 5-hmC abundance in GBM. Early tumor-related biomarkers may also be provided by the study of aberrant DNA hydroxymethylation in the blood of glioma patients. Therefore, we explored the patterns of TET transcripts in plasma samples and we found that their profiles were variously regulated, with significant value for TET2. The results of our study confirmed that DNA hydroxymethylation is an important mechanism involved in the pathogenesis of gliomas, with particular reference to glioblastoma. Heterogeneity of 5-hmC and TET proteins expression across GBM may provide novel insight into define subtype-specific patterns of hydroxymethylome, and thus help to interpret the heterogeneous outcomes of patients with the same disease.

Keywords: epigenetics, 5-hydroxymethylcytosine, ten-eleven translocation enzymes, brain tumors, glioblastoma

INTRODUCTION

The vast majority (80%) of malignant brain tumors is represented by gliomas (1). They have been classified by the World Health Organization into four grades, with Grade IV glioblastoma (GBM) as the most aggressive form. From 2016 the WHO grading is based on histological and molecular characteristics that are observed amongst various stages of gliomas (2). Many studies focused on
genomic and transcriptomic profiles of human gliomas demonstrated that although histologically similar, they constitute distinct subtypes (3–5) that are associated with different survival outcomes (6, 7). Therefore, systematic molecular analysis of human gliomas is essential for their comprehensive understanding. Aberrations in genes and molecular pathways, including IDH1/IDH2 and H3.1/H3.3 mutation or loss of TP53 tumor suppressor gene, can be used together with histopathological findings for gliomas classification (8, 9).

However, dysregulation of epigenomes seems to be the primary molecular mechanism involved in the pathogenesis of human gliomas. Epigenetic alterations, such as modifications of DNA (10, 11) and histones (12, 13), nucleosome remodeling (14, 15) and RNA-mediated silencing (16–18) are pointed out as a source of gliomas phenotypic heterogeneity. DNA methylation is the best-studied epigenetic change in this field (19–21), but some reports revealed the existence of other modifications in DNA methyleone.

The ten-eleven translocation (TET) enzymes can alter DNA methylation status by converting 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), and later to 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) (22). 5-hmC may act as a transient intermediate in the process of 5-mC demethylation, as well as, may epigenetically regulate gene expression. Several reports found the relationship between 5-hmC level and glioma grades (10, 23–26). However, 5-hmC modification and its direct effect on gliomas biology need to be investigated.

Here, we picture the TET-dependent hydroxymethylation patterns in human gliomas. Using solid tumor tissues samples we demonstrate heterogeneity in 5-hmC expression across glioblastoma which can provide novel insight into define subtype-specific patterns of 5-hmC, and thus help to interpret the heterogeneous outcomes of patients with the same disease.

MATERIALS AND METHODS

Clinical Samples

34 pairs of matched glioma tissues and blood samples were collected during standard neurosurgical tumor removals at the Department of Neurosurgery, Institute of Psychiatry and Neurology (Warsaw, Poland). Additionally, five independent random controls of blood samples were obtained from healthy volunteers. All solid tissues were submerged in the stayRNA solution (A&A Biotechnology) and stored at −80°C. Blood was collected into EDTA-treated tubes and centrifuged at 3500 rpm (MPW, Centrifuge MPW-350R, Rotor 1236B) for 10 min at 4°C. Then supernatant (plasma) was immediately transferred into the clean Eppendorf tubes and stored at −80°C.

5-hmC Quantification

The absolute level of 5-hmC in genomic DNA, previously extracted from 34 glioma tissues, was estimated with the EpiJET 5-hmC and 5-mC Analysis Kit (ThermoFisher Scientific). Briefly, 100 ng of DNA was glucosylated by T4 phage β-glucosyltransferase (T4 BGT), followed by subsequent digestion with Epi MsPi and Epi HpaII enzymes. Then the percentage of cytosine modifications within CCGG sites was determined by quantitative real-time PCR (qRT-PCR) with a primer pair flanking recognition sequence. Primer sequences were as follows:

- primer1_forward 5′-CTGTCATGGTGACAAAGGCATC-3′
- primer2_reverse 5′-CAGGATTTCTCTATTATGAAGACCTTG-3′

The experiment was run in triplicate and the amount of 5-hmC was calculated as a percentage based on controls included in the kit.

Quantitative Real-Time PCR

Following Chomczynski’s protocol (27), total RNA of glioma tissues was extracted by TRIzol Reagent (Life Technologies), whereas Total RNA Mini Concentrator Kit (A&A Biotechnology) was used for the extraction of RNA from plasma samples. The concentration and purity of RNA samples were assessed by measuring the 260/280 ratio of absorbance values with the Synergy H4 spectrophotometer (BioTek). cDNA was synthesized from 500 ng of RNA using random hexamers and TaqMan Reverse Transcription Reagents (ThermoFisher Scientific) according to the manufacturer’s instructions. Transcript levels of TET family genes were determined by the quantitative real-time PCR using 5x HOT FirePol EvaGreen qPCR Mix (Solis Biodyne) and primer sets for TET1, TET2, TET3, and the housekeeping gene GAPDH. The primer sequences are listed in Supplementary Table S1. All samples were run in triplicate, and data were normalized to the expression of GAPDH (28), according to the ΔCt method. While the ΔΔCt method was applied for relative quantification in blood samples.

Western Blot

Thirty-four human glioma tissues were homogenized with TissueLyser LT homogenizer (Qiagen) in lysis buffer containing 2% SDS, pH 6.8 and protease inhibitors (Sigma). According to the protocol of Ericsson et al. (29), homogenates were incubated at 70°C and shaking at 1400 rpm (BioSan, Thermo-Shaker TS-100) for 10 min and then centrifuged at 12000 rpm (Eppendorf, Centrifuge 5415R, Rotor F45-24-11) for 5 min. The concentration of protein extracts was determined with the Bradford protein assay (Sigma). 15 µg of each protein sample was separated with 7% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes using the Bio-Rad MINI Protein system. Immunoblotting with primary antibodies against TET1, TET2, TET3 (1:3000, ThermoFisher Scientific) and GAPDH (1:5000, Millipore) was performed overnight at 4°C, whereas secondary antibodies (mouse and a-rabbit, Vector) diluted 1:10000 were incubated with the membranes for one hour at room temperature. Blots were visualized with the WesternBright Quantum detection system (Advansta) on the UVITEC Cambridge scanner. Densitometry analysis was conducted using GelAnalyzer 2010 software.

Statistical Analysis

GraphPad Prism 7.02 software was used to analyze the data. Statistical significance of differences between groups was determined by One-way ANOVA or nonparametric Kruskal-
Wallis tests followed by *post hoc* Tukey or Dunn analysis, as well as with Mann-Whitney U test (*p < 0.05, **p < 0.01, ***p < 0.001). The results are presented as the mean ± standard deviation of the mean (SD).

**RESULTS**

**Global Changes in 5-hmC Abundance in Gliomas**

So far, decreased 5-hmC levels have been presented in a variety of tumors (30–32), suggesting that the loss of 5-hmC may be considered as an epigenetic hallmark of the disease. To evaluate the global changes in 5-hmC abundance in human brain tumors, we selected DNA of 34 glioma samples represented by different WHO grades and analyzed them with EpiJET 5-hmC and 5-mC Analysis Kit and quantitative real-time PCR. Clinical and epigenetic characteristics of glioma samples are shown in Table 1.

As can be seen in Figure 1 and Table 1, gliomagenesis has generated the changes of DNA hydroxymethylation. The 5-hmC expression correlated negatively with WHO grading, ranged from 8.2% in Grade II gliomas to 3.0% in Grade IV-low5-hmC GBM. Significant differences were observed between Grades II and III (p < 0.01), as well as Grades II and IV-low5-hmC (p < 0.01). While we observed a decreasing trend in 5-hmC expression with a higher tumor stage, we documented a strong elevation in 5-hmC level in around 30% of Grades IV GBM (Grade IV-high5-hmC). In this study group, the 5-hmC level was 20% and was significantly higher than in Grade IV-low5-hmC samples (3%, p < 0.001). To our knowledge, this is one of the few reports describing high variability in 5-hmC abundance at the tumor mass (10, 24). To clarify observed diversity, the GBMs samples were categorized according to their *IDH1* and developmental status. The results had not revealed molecular differences between both categories in this scope. A great majority of samples (95%) were primary glioblastomas, while all of them demonstrated the absence of mutation in *IDH1* gene.

Recognized differences might be a consequence of alterations in the expression of TET enzymes that catalyze the conversion of 5-mC to 5-hmC.

**TET Expression in Gliomas**

To define the impact of TET enzymes on changes in DNA hydroxymethylation, we analyzed their expression at the gene and protein levels in solid tumor tissues. Quantitative real-time PCR was performed to examine the mRNA expression of *TET* family genes (*TET1, TET2, and TET3*) in 34 samples, including 6 Grade II gliomas, 7 Grade III gliomas and 21 Grade IV GBM. We found that the relative mRNA levels of all three *TET* genes were strongly reduced during glioma grades (Figures 2A, C, E). Their downregulation was significantly higher in Grade IV GBM in comparison with Grade II gliomas (*TET1* and *TET3* p < 0.001, *TET2* p < 0.01) and Grade III gliomas (*TET1* p < 0.001, *TET2* and *TET3* p < 0.01). As the decline in *TET* mRNA was associated with glioma grades and 5-hmC expression, we determined the levels of *TET* transcripts in two groups with high variability in total 5-hmC abundance across GBM (Grade IV-low5-hmC and Grade IV-high5-hmC, Figure 1). There were no significant differences in *TET1* (p = 0.1322), *TET2* (p = 0.2434) and *TET3* (p = 0.8208) mRNA levels between glioblastoma Grade IV-low5-hmC.

---

**Table 1**

Characteristics of glioma patients.

| WHO grade | II | III | IV-low 5-hmC | IV-high 5-hmC |
|-----------|----|-----|--------------|---------------|
| Number of patients | 6  | 7   | 15           | 6             |
| Age at diagnosis (years) | | | | |
| Mean | 39.3 | 41.4 | 65.9 | 63.2 |
| Range | 24 - 54 | 26 - 59 | 53 - 77 | 52 - 77 |
| Gender | | | | |
| Male/Female | 3/3 | 4/3 | 9/6 | 3/3 |
| Hemisphere | | | | |
| Left/Right | 1/5 | 4/3 | 8/7 | 1/5 |
| Location | | | | |
| Frontal | 2 | 2 | 5 | – |
| Temporal | 3 | 5 | 4 | 4 |
| Parietal | 1 | – | 2 | – |
| Occipital | – | – | 4 | 2 |
| Tumor status | | | | |
| Primary/Recurrent | 5/1 | 6/1 | 15/0 | 5/1 |
| *IDH1* status | | | | |
| *IDH1* wild-type | 6 | 6 | 15 | 6 |
| *IDH1* mutant | 0 | 1 (R132G) | 0 | 0 |
| 5-hmC (%) | 8.2 | 3.5 | 3.0 | 20.0 |
and 150 kDa (p < 0.01, p < 0.05), TET2224 kDa (p < 0.001) and TET3194 kDa (p < 0.05) protein levels between GBM Grade IV- low5-hmC and Grade IV-high5-hmC. Differences among group means were evaluated by one-way ANOVA test (**p < 0.01, ***p < 0.001).

FIGURE 1 | Global 5-hmC abundance (%) in gliomas. Increasing WHO grades of glioma are associated with a continuous decline in 5-hmC levels, except for glioblastoma (IV-low5-hmC and IV-high5-hmC). Differences among group means were evaluated by one-way ANOVA test (**p < 0.01, ***p < 0.001).

hmC and Grade IV-high5-hmC (Figures 2B, D, F). Next, we evaluated the levels of TET proteins in the same samples by Western blot. Expression levels of each TET proteins are shown in Supplementary Table S2. Immunoblotting revealed the absence of TET1 isoform at 235 kDa, which is mainly detected in embryonic stem cells. But, two additional bands at 162 kDa and 150 kDa were found in the majority of instances. TET2 and TET3 isoforms were discovered at 224 and 194 kDa, respectively (Figure 3A). As in the case of TET transcripts expression (Figures 2A, C, E), levels of TET proteins were negatively associated with advanced stages of gliomas. From Grade II gliomas to Grade IV GBM, we noticed 2-, 4- and 6-fold reduction in TET1162 and 150 kDa, TET2224 kDa and TET3194 kDa levels, respectively. Interestingly, in Grade IV samples, we observed high variability in TET isoforms expression pattern, which could affect 5-hmC abundance. Quantification of normalized values showed significant differences in TET1162 and 150 kDa (p < 0.01, p < 0.05), TET2224 kDa (p < 0.001) and TET3194 kDa (p < 0.05) protein levels between GBM Grade IV-low5-hmC and Grade IV-high5-hmC (Figures 3B–E). These findings suggested the potential role of TET proteins patterns in setting the 5-hmC level in Grade IV glioblastoma.

TET Transcripts Profiling in Plasma Samples

The prospect of distinguishing the aberrant DNA hydroxymethylation in the blood of glioma patients may indicate a powerful tool for early cancer detection or monitoring its progress. To explore the potential diagnostic features of TET transcripts profiling, we performed the quantitative real-time PCR on 34 plasma samples obtained from patients with Grade II or III or IV gliomas, and 5 healthy controls. Expression of TET genes was observed in the majority of examined samples, followed by specific numbers for TET1 (control: 80% vs. Grade: II-83%, III-57%, IV-70%), TET2 (control: 80% vs. Grade: II-83%, III-71%, IV-91%) and TET3 (control: 80% vs. Grade: II-50%, III-86%, IV-91%) transcript. Our results confirmed that the employed method was sensitive to low-input mRNA presented in plasma samples. The further analysis evaluated the relative mRNA levels of TET genes in plasma samples obtaining from patients with different WHO grades gliomas and compared them to healthy controls (Figures 4A–C). The results displayed various profiles for each transcript. While TET1 characterized slightly lower expression than control, TET3 was similar to control values. The expression of both transcripts was unaffected by WHO grading (Figures 4A, C). Whereas, the level of TET2 was significantly increased in plasma samples derived from patients with Grade II gliomas compared to controls (p < 0.01, Figure 4B). Validation of our preliminary results in a larger population of patients is needed to evaluate their use as potential biomarkers for early-stage gliomas diagnostics.

DISCUSSION

Currently, the molecular landscape of brain tumors is described by epigenetic mechanisms include DNA methylation and hydroxymethylation (10, 11), histone modifications (12, 13), nucleosome remodeling (14, 15) and RNA-mediated silencing (16–18), that may clarify their etiologic evolution. Recently rediscovered, oxidized form of 5-methylcytosine (5-hmC) may act as a transient intermediate in the process of 5-mC demethylation or may epigenetically mark the cellular state itself with different biological roles.

In the present study, we characterize the epigenetic profile of DNA hydroxymethylation in human gliomas. Decreased level of 5-hmC was observed in glioma patients compared to healthy controls (33–35), but also it was related to glioma grades (10, 23–26). Our results confirm that the loss of 5-hmC is a hallmark of high-grade gliomas. However, we documented a significant increase of global 5-hmC abundance in almost a third of Grades IV GBM. This is one of the few findings that demonstrated heterogeneity in 5-hmC expression across the bulk of the glioblastoma (10, 24). According to recent research, the intra-tumoral diversity of 5-hmC levels among single GBM cells, that represent the proliferative, stem-like and tumorigenic states, could clarify unexpected results (36). But, dysregulation of TET enzymes function may be a possible biological explanation for the observed variability as well. The influence of TETs, including their genetic alterations and subcellular localization, on 5-hmC status in glioma cells, was described by several studies (23–25, 37, 38). Recently, epigenetic repression of histone marks (H4K16ac, H3K4me3, H3K9ac, H3K36me3, H3K4me1, H3K27ac) in TET3 gene has been postulated as a driver of glioblastoma development via genome-wide alteration of 5-hmC (39). Generally, it is believed that the decline in TET genes expression causes a widespread reduction of 5-hmC and poorer
prognosis in glioma patients. We found that TET1, TET2, TET3 mRNA, and 5-hmC levels were decreased during glioma grades. However, similarly to Jin and Glowacka results (40, 41), there was no correlation between expression of TET transcripts and variability in 5-hmC abundance across the bulk of the glioblastoma. To define the complete impact of TETs on changes in DNA hydroxymethylation, we evaluated their protein levels in the same samples. Proteins produced by the TET2 and TET3 isoforms were expressed as expected bands at 224 kDa and 194 kDa. Instead of the 235 kDa canonical TET1 protein, we found two short isoforms (162 kDa and ~150 kDa). According to previous reports, they are exclusively activated from an alternate promoter in somatic cancer cells (42, 43). The levels of TET proteins, just as TET transcripts, were negatively associated with high-grade gliomas. However, Grade IV GBM samples were more variable in this field. Significant heterogeneity in the expression of TET2 protein in glioblastoma was also noted by Briand (44). We furthermore pointed out the relation between variable levels of TET proteins and
5-hmC abundance across glioblastoma. Our findings suggest that the regulation of TET transcription and translation can be made in a different way. For example, this observed imbalance may be a result of different actions of transcription factors, RNA binding proteins, miRNAs targeting mRNA or post-translational modifications (like phosphorylation, acetylation, glycosylation, etc.). Based on the patient-derived glioma stem cells (GSCs) model, the transcription factor (SOX2)-oncomiR (miR-10b-5p)-TET2 axis was identified, which plays an important role in promoting GBM oncogenesis (45).

However, it is one of many potential mechanisms involved in glioblastoma growth.

In summary, we demonstrated that expression patterns of TET proteins and the 5-hmC abundance are changed in Grade IV GBM, but the molecular mechanism of this process still needs to be clarified.

Recently, many studies on gliomas indicated the presence of circulating cell-free coding and non-coding nucleic acids in blood or other biofluid samples (46–48). Therefore, liquid
biopsy has become a new diagnostic tool that may establish and track the stage of cancer with particular biomarkers. Cai’s group, for example, has developed a noninvasive 5-hmC detection method in circulating cell-free DNA of glioma patients, which was able to distinguish the difference between GBM and lower-grade gliomas regardless of IDH1 mutation status (49). Here, we explore the potential diagnostic features of TET transcripts in plasma samples obtained from patients with gliomas. All three TET transcripts were detected in plasma, but their profiles differed from those in solid tissue. We showed that the plasma relative mRNA level for TET1 was decreased in every stage of glioma, while the TET3 level remained unchanged. The most promising results were provided by TET2 gene that was significantly increased in Grade II glioma. Validation of our preliminary results in a larger population of patients is needed to evaluate their use as potential biomarkers for glioma diagnostics.

To conclude, we found that global abundance of 5-hmC was negatively correlated with glioma WHO grades and variable across the bulk of the glioblastoma. It was followed by various TET proteins patterns in solid tumor tissues. In contrast, profiles of TET transcripts in plasma samples displayed its heterogeneity. However, significant overexpression of TET2 in Grade II gliomas might offer a new tool for effective diagnosis of lower-grade glioma patients. Our findings provide novel information about the potential role of TET epigenetic regulation in human gliomas, with particular reference to glioblastoma.

**DATA AVAILABILITY STATEMENT**

All data generated during this study are included in the article. Further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The study was conformed to the standards set by the Declaration of Helsinki and approved by the ethics committee of the Centre of Postgraduate Medical Education (code: 34/PB/2017). Written informed consent was obtained from participants prior to specimen collection.

**AUTHOR CONTRIBUTIONS**

MG designed all experiments, interpreted the results, and wrote the manuscript. AB-P, GL performed the experiments, analyzed the data. KZ-B performed part of molecular analysis. AS-S, MC contributed to sample collection and registered clinical information. MS and MR managed sample collection; critically commented on the manuscript. All authors read and approved the final version.

**FUNDING**

This study was supported by a statutory grant 501-1-027-03-19 from the Centre of Postgraduate Medical Education in Warsaw.

**ACKNOWLEDGMENTS**

The authors thank Mrs. Monika Kubiak for help with the management of clinical information.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fonc.2022.621460/full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fonc.2022.621460/full#supplementary-material)
39. Carella A, Tejedor JR, Garcia MG, Urdinguio RG, Bayon GF, Sierra M, et al. Epigenetic Downregulation of TET3 Reduces Genome-Wide 5hmC Levels and Promotes Glioblastoma Tumorigenesis. *Int J Cancer* (2020) 146:373–87. doi: 10.1002/ijc.32520

40. Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, et al. 5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers But Its Levels Do Not Correlate With IDH1 Mutations. *Cancer Res* (2011) 71:7360–5. doi: 10.1158/0008-5472.CAN-11-2023

41. Glowacka WK, Jain H, Okura M, Maimaitiming A, Mamatjan Y, Nejad R, et al. 5-Hydroxymethylcytosine Preferentially Targets Genes Upregulated in Isocitrate Dehydrogenase 1 Mutant High-Grade Glioma. *Acta Neuropathol* (2018) 135:617–34. doi: 10.1007/s00401-018-1821-3

42. Zhang W, Xia W, Wang Q, Towers AJ, Chen J, Gao R, et al. Isoform Switch of TET1 Regulates DNA Demethylation and Mouse Development. *Mol Cell* (2016) 64:1062–73. doi: 10.1016/j.molcel.2016.10.030

43. Good CR, Madzo J, Patel B, Maegawa S, Engel N, Jelinek J, et al. A Novel Isoform of TET1 That Lacks a CXXC Domain Is Overexpressed in Cancer. *Nucleic Acids Res* (2017) 45:8269–81. doi: 10.1093/nar/gkx435

44. Briand J, Nadaradjane A, Vallette FM, Cartron P-F. The TET2 Expression Level Correlates With a Short Relapse Time in Glioblastoma Multiforme. *J Clin Epigenet* (2018) 4:12. doi: 10.21767/2472-1158.100097

45. Lopez-Bertoni H, Johnson A, Rui Y, Lal B, Sall S, Malloy M, et al. Sox2 Induces Glioblastoma Cell Stemness and Tumor Propagation by Repressing TET2 and Deregulating 5hmC and 5mC DNA Modifications. *Signal Transduct Target Ther* (2022) 7:37. doi: 10.1038/s41392-021-00857-0

46. Schweaderle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, et al. Detection Rate of Actionable Mutations in Diverse Cancers Using a Biopsy-Free (Blood) Circulating Tumor Cell DNA Assay. *Oncotarget* (2016) 7:9707–17. doi: 10.18632/oncotarget.7110

47. Mouliere F, Mair R, Chandrananda D, Marass F, Smith CG, Su J, et al. Detection of Cell-Free DNA Fragmentation and Copy Number Alterations in Cerebrospinal Fluid From Glioma Patients. *EMBO Mol Med* (2018) 10:e9323. doi: 10.15252/emmm.201809323

48. Piccioni DE, Achrol AS, Kiedrowski LA, Banks KC, Boucher N, Barkhoudarian G, et al. Analysis of Cell-Free Circulating Tumor DNA in 419 Patients With Glioblastoma and Other Primary Brain Tumors. *CNS Oncol* (2019) 8:CNS34. doi: 10.2217/cns-2018-0015

49. Cai J, Zeng C, Hua W, Qi Z, Song Y, Lu X, et al. An Integrative Analysis of Genome-Wide 5-Hydroxymethylcytosines in Circulating Cell-Free DNA Detects Noninvasive Diagnostic Markers for Gliomas. *Neurooncol Adv* (2021) 3:vdb049. doi: 10.1093/noajnl/vdab049

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Brągiel-Pieczonka, Lipka, Staśpińska-Symiec, Czyżewski, Żybura-Brodka, Sobstyl, Rybki and Grabiec. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.